Shares of Constellation Pharmaceuticals Inc (NASDAQ:CNST) have been given an average recommendation of “Buy” by the eight brokerages that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $18.33.
A number of research firms have recently commented on CNST. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Constellation Pharmaceuticals in a research note on Wednesday, June 5th. Zacks Investment Research cut shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. Finally, Oppenheimer boosted their target price on shares of Constellation Pharmaceuticals from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 2nd.
CNST opened at $9.58 on Thursday. Constellation Pharmaceuticals has a fifty-two week low of $4.01 and a fifty-two week high of $14.04. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.92 and a quick ratio of 6.92. The firm has a market capitalization of $240.52 million and a price-to-earnings ratio of -1.92.
Constellation Pharmaceuticals (NASDAQ:CNST) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. As a group, equities analysts anticipate that Constellation Pharmaceuticals will post -3.13 EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in the company. Svennilson Peter acquired a new position in Constellation Pharmaceuticals during the fourth quarter worth about $18,759,000. Casdin Capital LLC boosted its position in Constellation Pharmaceuticals by 18.4% during the fourth quarter. Casdin Capital LLC now owns 1,556,998 shares of the company’s stock worth $6,244,000 after acquiring an additional 242,255 shares during the last quarter. BlackRock Inc. boosted its position in Constellation Pharmaceuticals by 582.3% during the first quarter. BlackRock Inc. now owns 726,325 shares of the company’s stock worth $9,842,000 after acquiring an additional 619,868 shares during the last quarter. Vanguard Group Inc acquired a new position in Constellation Pharmaceuticals during the third quarter worth about $989,000. Finally, Vanguard Group Inc. acquired a new position in Constellation Pharmaceuticals during the third quarter worth about $989,000. 64.38% of the stock is owned by institutional investors and hedge funds.
Constellation Pharmaceuticals Company Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Recommended Story: Reverse Stock Split
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.